Adrian Rawcliffe

[Adrian Rawcliffe @adgraw]

@AJS77 @campbellclaret @UKChange The Y

[Adaptimmune @Adaptimmune]

$NEWS – Completed submission of the clinical module (Part 2) for our afami-cel rolling BLA. Afami-cel has the potential to be the first marketed engineered #TCR #celltherapy for a solid tumor indication. $ADAP #oncology

[Adaptimmune @Adaptimmune]

Today, we proudly announce the initiation of a rolling biologics license application (BLA) for afami-cel, our first-gen engineered TCR T-cell therapy targeting MAGE-A4. Completion of the submission is planned for mid-2023. #TCR #oncology

[Philadelphia Business Journal @PHLBizJournal]

Get to know John Lunger of Adaptimmune Therapeutics, one of our 2022 Veterans of Influence honorees. https://t.co/FHpaFlJsis

[Adrian Rawcliffe @adgraw]

@TammyMa68725095 huh

[John Maraganore 🇺🇸🇬🇷🇺🇦 @JMaraganore]

Our Nation and planet are extremely fortunate to have Moncef Slaoui on the front lines of Operation Warp Speed to advance safe and effective #covid19 vaccines and Rx!

[Adrian Rawcliffe @adgraw]

Moncef Slaoui answered the call because overcoming COVID-19 trumps politics and he cannot profit from this. If poisonous politics drives away expert, gifted, high integrity people like Moncef we will all suffer. @SenWarren @ewarren please make this right

[CBS Evening News with Tony Dokoupil @CBSEveningNews]

EXCLUSIVE: Pres. Trump’s vaccine czar responds to Sen. Warren’s charge that he’s potentially profiting from his role in the administration.

“You are publicly accusing me of being greedy, of being corrupt,” Moncef Slaoui says in a recording addressing Warren. “You are wrong."

[CBS Evening News with Tony Dokoupil @CBSEveningNews]

EXCLUSIVE: Pres. Trump’s vaccine czar responds to Sen. Warren’s charge that he’s potentially profiting from his role in the administration.

“You are publicly accusing me of being greedy, of being corrupt,” Moncef Slaoui says in a recording addressing Warren. “You are wrong."

[Adrian Rawcliffe @adgraw]

So very grateful to be able to work everyday for a future #Immune2Cancer.

[Adaptimmune @Adaptimmune]

What we do everyday – to create a future #Immune2Cancer – is to design, develop and deliver SPEAR T-cells for people with #cancer in our #clinicaltrials. Today we wear white for lifesaving #cancerresearch and everyone, including friends and families, living with cancer.
#CIM20

[Adrian Rawcliffe @adgraw]

Simple description of some very complex biology. #celltherapy #TheCancerRevolution

[Adaptimmune @Adaptimmune]

We are currently investigating our next-generation SPEAR T-cell therapy, ADP-A2M4CD8, in the SURPASS #clinicaltrial. Watch the video below to see how adding CD8 may improve the potency of our SPEAR T-#celltherapy!

[Adaptimmune @Adaptimmune]

At the #CARTCREU Summit, our colleague J Renwick was talking abt opps & challenges of running #celltherapy #clinicaltrials in #Europe, and how with our dedicated resource and expertise, we work successfully with some high quality #oncology #research centers in the region.

[Adrian Rawcliffe @adgraw]

Amongst the last out of #JPM20. Big conference for ⁦@Adaptimmune⁩. Responses in solid tumours, partnership with ⁦@AstellasUS⁩. Packed discussions with fellow travelers on the road to making cell therapy transformative for people with cancer. Looking forward to 2020

[Adrian Rawcliffe @adgraw]

Elliot is a superb leader, committed to people with cancer and the team @Adaptimmune. I am honored to be working with him to #SpearheadTCR #JPM20

[Adaptimmune @Adaptimmune]

We have an exciting leadership update! Dr. Elliot Norry has been appointed as Chief Medical Officer. After being with $ADAP for the past 4 years, we could not be more grateful that he will continue to be part of our team. Read more here: https://t.co/R9GbBOlraV #JPM2020

[Adrian Rawcliffe @adgraw]

Not sure the protocol of retweeting your own quote but whatever......really good news for people with cancer who might benefit from SPEAR T-cell therapy

[Adaptimmune @Adaptimmune]

NEWS: We are thrilled to share with the #cancer community that we have seen partial responses in 4 additional solid tumor indications – beyond the responses already observed in synovial #sarcoma! Read the press release here: https://t.co/nVGaXaoTOW
#JPM2020 $ADAP

[Adrian Rawcliffe @adgraw]

You know you are in San Francisco when the first thing in a CVS store is a basket of avocados. Bat are they organic? #notvegan #JPM20

[Adrian Rawcliffe @adgraw]

Very proud of the @adaptimmune team and our partners at centers everywhere that have worked tirelessly to develop ADP-A2M4 for people with synovial sarcoma. This is why we do it #SPEARTcells, #MondayMotivation #ArmingCells #AgainstCancer

[Adaptimmune @Adaptimmune]

#ESMO19 NEWS: Dr. @bvantine1 from @WUSTL will present updated synovial #sarcoma response data from our ongoing ADP-A2M4 pilot trial. Be sure to read the full results here: https://t.co/JBycbCSzuy

[AlpineImmuneSciences @AlpineImmuneSci]

Wonderful! The entire Alpine team is really excited to work with @Adaptimmune on next-generation cellular therapies. We have high hopes together we'll create products making a big difference in patients' lives.

https://t.co/bIhmkAcLpy

[Adaptimmune @Adaptimmune]

This week, Karen Miller joined us as SVP Pipeline Research in our @MiltonPark offices. Rafael Amado President R&D said “Her broad knowledge of immunology and strong history of managing teams will complement the team's current capabilities and skills.”

#immunotherapy $ADAP

[Adaptimmune @Adaptimmune]

This #IWD2019, learn how Adaptimmune’s Jo Brewer has been at the forefront of T-cell therapy discovery. Read Jo’s story here: (https://t.co/ReszHIvMvc) #WomensHistoryMonth #BalanceforBetter